NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

細胞治療藥、基因治療藥用藥物輸送設備的全球市場 (2020-2030年):市場預測 (各產品類型、醫藥品、地區)、競爭分析

Global Cell and Gene Therapy Drug Delivery Devices Market: Focus on Product Type, Commercialized Drug Delivery Devices, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030

出版商 BIS Research Inc. 商品編碼 995936
出版日期 內容資訊 英文 288 Pages
商品交期: 最快1-2個工作天內
價格
細胞治療藥、基因治療藥用藥物輸送設備的全球市場 (2020-2030年):市場預測 (各產品類型、醫藥品、地區)、競爭分析 Global Cell and Gene Therapy Drug Delivery Devices Market: Focus on Product Type, Commercialized Drug Delivery Devices, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030
出版日期: 2021年03月15日內容資訊: 英文 288 Pages
簡介

全球細胞治療藥、基因治療藥用藥物輸送設備的市場規模在預測期間內預計以16.61%的年複合成長率發展,從2019年的5萬5750美元,成長到2030年37萬5130美元的規模。

癌症和慢性疾病增加,對細胞、基因治療藥市場的資金提供增加,罕見疾病的新治療方法的開發需求高漲,生物醫藥品的R&D費增加,細胞、基因治療藥的FDA核准數和臨床試驗數增加等要素,預計促進該市場的成長。

本報告提供全球細胞治療藥、基因治療藥用藥物輸送設備的市場調查,市場定義和概要,新型冠狀病毒感染疾病 (COVID-19) 以及其他的市場影響因素分析,法律制度,償付趨勢,技術、專利趨勢,開發平台趨勢,市場規模的變化、預測,產品類型、醫藥品、地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等資訊彙整。

摘要整理

第1章 技術定義

第2章 調查範圍

第3章 重要課題

第4章 調查手法

第5章 市場概要

第6章 全球市場、成長可能性

  • 概要
  • 開發平台分析
  • 成長可能性
  • 開發、商品化情勢
  • COVID-19的影響

第7章 新興技術情勢

  • 潛在的技術
  • 微晶片技術
  • 奈米技術為基礎的藥物輸送設備
  • 基因治療的脂質奈米粒子

第8章 市場動態

  • 影響分析
  • 市場推動因素
  • 市場抑制因素
  • 市場機會

第9章 產業考察

  • 法規方案
  • 價格設定、償付

第10章 專利形勢

第11章 市場分析、預測:各產品類型

  • 概要
  • 視網膜下注射導管
  • 延長管
  • 靜脈內導管
  • 殺菌胰島素注射器
    • 尺寸1.0 ML、31計量針
    • 尺寸0.5 ML、22計量針
  • 預填充式注射器
    • 尺寸1.0 ML、22-26計量針
    • 尺寸4.0 ML、22-26計量針
  • 輸液袋子
    • 尺寸10∼50 ML
    • 尺寸68 ML
    • 尺寸60 ML
    • 尺寸65 ML

第12章 市場分析、預測:各類醫藥品

  • 成藥
    • Luxturna
    • Kymriah
    • Provenge
    • Zolgensma
    • Yescarta
    • Strimvelis

第13章 市場分析、預測:各地區、主要國家

  • 概要
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 荷蘭
    • 俄羅斯
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 澳洲
    • 韓國
    • 印度
    • 新加坡
    • 其他
  • 南美
    • 巴西
    • 墨西哥
    • 其他
  • 其他地區

第14章 競爭情形

  • 主要的展開、策略
  • 市場佔有率分析

第15章 企業簡介

  • Amgen Inc.
  • Bausch & Lomb Incorporated.
  • Becton, Dickinson and Company
  • Bluebird bio, Inc.
  • Castle Creek Biosciences, Inc. (Fibrocell Science, Inc.)
  • Dendreon Pharmaceuticals LLC.
  • Helixmith Co., Ltd (ViroMed Co., Ltd)
  • Human Stem Cells Institute
  • Kite Pharma, Inc.
  • Kolon TissueGene, Inc.
  • Novartis AG
  • Orchard Therapeutics plc.
  • Pfizer, Inc.
  • Renova?Therapeutics
  • Spark Therapeutics, Inc.
  • uniQure N.V.
  • Vericel Corporation
目錄
Product Code: BHL1036SA

"Global Cell and Gene Therapy Drug Delivery Devices Market to Reach $375.13 Thousand by 2030."

Market Report Coverage - Cell and Gene Therapy Drug Delivery Devices

Market Segmentation

  • Product Type - Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe (1.0 ml, and 0.5 ml), Prefilled Syringe (1.0 ml, and 4.0 ml), and Infusion Bags (10 ml to 50 ml, 68 ml, 60 ml, and up to 65 ml).
  • Commercialized Drugs - Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, and Strimvelis

Regional Segmentation

  • North America - U.S., Canada
  • Europe - Germany, France, Italy, U.K., Spain, Netherlands, Russia, and Rest-of-Europe
  • Asia-Pacific - China, Japan, India, South Korea, Singapore, Australia, and Rest-of-Asia-Pacific (RoAPAC)
  • Latin America - Brazil, Mexico, and Rest-of-the-Latin America
  • Rest-of-the-World

Growth Drivers

  • Increasing Prevalence of Cancer and Chronic Diseases
  • Increased Funding in Cell and Gene Therapy Market
  • Rising Number of the FDA Approvals of Cell and Gene Therapies & Clinical Trials

Market Challenges

  • Stringent Government Regulations
  • Injuries and Infections Caused by Needles

Market Opportunities

  • Strong Pipeline and Drug Approvals of Cell and Gene Therapies

Key Companies Profiled

Amgen, Inc., Bausch & Lomb Incorporated, Becton, Dickinson and Company, Bluebird bio, Inc., Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.), Dendreon Pharmaceuticals LLC., Helixmith Co., Ltd (ViroMed Co., Ltd), Human Stem Cell Institute, Kite Pharma, Inc., Kolon Tissue Gene, inc., Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., Renova Therapeutics, Spark Therapeutics, Inc., uniQure N.V., and Vericel Corporation.

Key Questions Answered in this Report:

  • What are cell and gene therapy drug delivery devices?
  • What is the list of commercialized cell and gene therapies available in the market?
  • How did the cell and gene therapy drug delivery devices market evolve, and what is its scope in the future?
  • What are the major market drivers, challenges and opportunities in the global cell and gene therapy drug delivery devices market?
  • What are the key developmental strategies that are being implemented by the key players to sustain in this market?
  • How did the emerging technology landscape of cell and gene therapy drug delivery devices look like?
  • What will be the impact of COVID-19 on this market?
  • What will be the impact of COVID-19 on cell and gene therapy drug delivery devices companies?
  • What will be the impact of COVID-19 on supply chain of cell and gene therapy drug delivery devices market?
  • What are the guidelines implemented by different government bodies to regulate the approval of cell and gene therapy drug delivery devices market?
  • How the investments by government organizations will affect the global cell and gene therapy drug delivery devices market?
  • What was the market size of the leading segments and sub-segments of the global cell and gene therapy drug delivery devices market in 2019?
  • How will the industry evolve during the forecast period 2020- 2030?
  • What will be the growth rate of the cell and gene therapy drug delivery devices market during the forecast period?
  • How will each of the segments of the global cell and gene therapy drug delivery devices market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2030?
  • Which product segment, and commercialized drug segment is expected to register the highest CAGR for the cell and gene therapy drug delivery devices market?
  • What is the market size of cell and gene therapy drug delivery devices market in different countries of the world?
  • Which geographical region will contribute to the highest sales of cell and gene therapy drug delivery devices market?
  • What are the reimbursement scenario and regulatory structure for the cell and gene therapy drug delivery devices in different regions?
  • What are the key strategies incorporated by the players of global cell and gene therapy drug delivery devices market, to sustain the competition and retain their supremacy?

Market Overview

Cell and gene therapy drug delivery industry is a transformative industry whose full potential is only just beginning to emerge. Cell and gene therapy involves the extraction of cells, protein, or genetic material (DNA) from the donor, and altering them to provide highly personalized therapy. Cell and gene therapies may offer longer-lasting effects than traditional medicines. One of the significant drugs of the cell and gene therapy industry is CAR-T cell-based medicines, which include both cell therapy and gene therapy. Various market players are actively investing in the research and development of the cell and gene therapy industry. The players are offering improved and new products, which meet the critical needs of patients. The global cell and gene therapy drug delivery devices market was valued at $55.75 thousand in 2019, and is expected to reach $375.13 thousand by 2030, registering a CAGR of 16.61% during the forecast.

The growth is attributed to major drivers in this market such as increasing prevalence of cancer and chronic diseases, increased funding in cell and gene therapy market, rising need to develop novel treatment options for rare disease, and rising biopharmaceutical R&D expenditure, and rising number of the FDA approvals of cell and gene therapies & clinical trials. The market is expected to grow at a significant growth rate due to various potential opportunities of growth that lie within its domain, which include drug approvals and strong pipeline of cell and gene therapies.

Various new cell and gene-based therapy approaches use biological engineering to improve the immune system's capacity to fight disease while sparing healthy tissues in the body. For instance, there are antibody-based therapies that can make T-cells more effective by increasing their interactions with cancer cells. Other modifications, such as adding complexity to the CAR-T and cancer cell interaction, which can further sharpen T-cells' cancer-targeting ability by reducing damage to normal cells. The increase in geriatric population and increasing number of cancer cases, and genetic disorders across the globe are expected to translate into a significantly higher demand for cell and gene therapy drug delivery devices market.

Furthermore, the companies are investing huge amount in research and development of cell and gene therapies and associated drug delivery devices products. The clinical trial landscape of various genetic and chronic diseases has been on the rise in the recent years, this will fuel the cell and gene therapy drug delivery devices market in future.

Within the research report, the market is segmented based on product type, commercialized drugs, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the application of precision medicine on a global level has created a buzz among companies to invest in the development of novel cell and gene therapy drug delivery devices. Due to the diverse product portfolio and intense market penetration, Novartis AG, Kite Pharma Inc., and Dendreon Pharmaceuticals LLC. have been the pioneers in this field and been the major competitors in this market. The other major contributors of the market include companies such as Vericel Corporation, Amgen Inc., Bausch & Lomb Incorporated, Spark Therapeutics, Inc., and Becton, Dickinson and Company.

Based on region, North America holds the largest share of cell and gene therapy drug delivery devices market due to substantial investments made by biotechnology and pharmaceutical companies, improved healthcare infrastructure, rise in per capita income, early availability of approved therapies, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.

Table of Contents

Executive Summary

1 Technology Definition

  • 1.1 Inclusion and Exclusion Criteria
    • 1.1.1 Inclusions
    • 1.1.2 Exclusions

2 Research Scope

3 Key Questions Answered in the Report

4 Research Methodology

  • 4.1 Cell and Gene Therapy Drug Delivery Devices: Research Methodology
  • 4.2 Primary Data Sources
  • 4.3 Secondary Data Sources
  • 4.4 Market Estimation Model
  • 4.5 Criteria for Company Profiling

5 Market Overview

  • 5.1 Introduction
  • 5.2 Cell and Gene Therapies and Drug Delivery Devices Industry
  • 5.3 Cell and Gene Therapy Drugs and Their Clinical Importance
  • 5.4 Cell and Gene Therapy Drug Delivery Devices Market: Current Scenario
  • 5.5 Cell and Gene Therapy Drug Delivery Devices Market: Future Perspective

6 Global Cell and Gene Therapy Drug Delivery Devices Market and Growth Potential, 2020-2030

  • 6.1 Overview
  • 6.2 Pipeline Analysis
    • 6.2.1 Drug Delivery Systems in Development: Current Scenario
      • 6.2.1.1 Ongoing Clinical Trials of Drug Delivery Systems
      • 6.2.1.2 Limitations of Cell and Gene Therapy Drug Delivery Devices
      • 6.2.1.3 Recent Advancements in Gene Therapy Drug Delivery
  • 6.3 Cell and Gene Therapy Drug Delivery Devices Market and Growth Potential
  • 6.4 Cell and Gene Therapy Drug Development and Commercialization Landscape
  • 6.5 Impact of COVID-19 on Cell and Gene Therapy Drug Delivery Devices Market
    • 6.5.1 Impact of COVID-19 on Global Cell and Gene Therapy Drug Delivery Devices Market Growth Rate
    • 6.5.2 Impact of COVID-19 on Supply Chain of Cell and Gene Therapy Drug Delivery Devices Market
    • 6.5.3 Clinical Trial Disruptions and Resumptions

7 Emerging Technology Landscape

  • 7.1 Potential Technologies in Cell and Gene Therapy Drug Delivery Devices Market
  • 7.2 Microchip Technology
  • 7.3 Nanotechnology-Based Drug Delivery Devices
  • 7.4 Lipid Nanoparticles in Gene Therapy

8 Market Dynamics

  • 8.1 Impact Analysis
  • 8.2 Market Drivers
    • 8.2.1 Increasing Prevalence of Cancer and Chronic Diseases
    • 8.2.2 Increased Funding of Cell and Gene Therapies
    • 8.2.3 Rising Number of FDA Approvals of Cell and Gene Therapies, and Clinical Trials
  • 8.3 Market Restraints
    • 8.3.1 Stringent Legal Requirements and Regulations
    • 8.3.2 Injuries and Infections Caused by Needles
  • 8.4 Market Opportunities
    • 8.4.1 Strong Pipeline of Cell and Gene Therapies

9 Industry Insights

  • 9.1 Regulatory Scenario of Cell and Gene Therapy Drug Delivery Devices Market
    • 9.1.1 Overview
    • 9.1.2 Risk Assessment of Medical Devices
    • 9.1.3 Regulation of Medical Devices in the U.S.
      • 9.1.3.1 Food and Drug Administration (FDA)
      • 9.1.3.2 Food and Drug Administration (FDA) Regulations Modification
    • 9.1.4 Regulation of Medical Devices in Europe
      • 9.1.4.1 Regulations in Europe - Highlights
      • 9.1.4.2 EU Regulatory Pathway for Medical Device
      • 9.1.4.3 Federal Agencies of EU Member States
      • 9.1.4.4 European Commission Regulations Modification
    • 9.1.5 Regulation of Medical Devices in Asia-Pacific
      • 9.1.5.1 Overview
      • 9.1.5.2 Regulatory and Market Access Challenges in Asia-Pacific
      • 9.1.5.3 Regulatory Environment for Medical Devices in China
  • 9.2 Pricing and Reimbursement of Cell and Gene Therapy Drug Delivery Devices

10 Patent Landscape

11 Global Cell and Gene Therapy Drug Delivery Devices Market (by Product Type)

  • 11.1 Overview
  • 11.2 Subretinal Injection Cannula
  • 11.3 Extension Tube
  • 11.4 Intravenous Catheter
  • 11.5 Sterile Insulin Syringe
    • 11.5.1 Sterile Insulin Syringe (Size 1.0 ML, 31-Gauge Needle)
    • 11.5.2 Sterile Insulin Syringe (Size 0.5 ML, 22 Gauge Needle)
  • 11.6 Pre-Filled Syringe
    • 11.6.1 Pre-Filled Syringe (Size 1.0 ML, 22-26 Gauge Needle)
    • 11.6.2 Pre-Filled Syringe (Size 4.0 ML, 22-26 Gauge Needle)
  • 11.7 Infusion Bags
    • 11.7.1 Infusion Bags (Size 10 ML to 50 ML)
    • 11.7.2 Infusion Bags (Size 68 ML)
    • 11.7.3 Infusion Bags (Size 60 ML)
    • 11.7.4 Infusion Bags (Size Up to 65 ML)

12 Global Cell and Gene Therapy Drug Delivery Devices Market (by Commercialized Drugs)

  • 12.1 Commercialized Drugs
    • 12.1.1 Luxturna
    • 12.1.2 Kymriah
    • 12.1.3 Provenge
    • 12.1.4 Zolgensma
    • 12.1.5 Yescarta
    • 12.1.6 Strimvelis

13 Global Cell and Gene Therapy Drug Delivery Devices Market (by Region)

  • 13.1 Overview
  • 13.2 North America
    • 13.2.1 U.S.
      • 13.2.1.1 Approved Products
      • 13.2.1.2 Market Size and Forecast
      • 13.2.1.3 Key Developments
    • 13.2.2 Canada
      • 13.2.2.1 Approved Products
      • 13.2.2.2 Market Size and Forecast
      • 13.2.2.3 Key Developments
  • 13.3 Europe
    • 13.3.1 Germany
      • 13.3.1.1 Approved Products
      • 13.3.1.2 Market Size and Forecast
      • 13.3.1.3 Key Developments
    • 13.3.2 France
      • 13.3.2.1 Approved Products
      • 13.3.2.2 Market Size and Forecast
      • 13.3.2.3 Key Developments
    • 13.3.3 U.K.
      • 13.3.3.1 Approved Products
      • 13.3.3.2 Market Size and Forecast
    • 13.3.4 Italy
      • 13.3.4.1 Approved Products
      • 13.3.4.2 Market Size and Forecast
      • 13.3.4.3 Key Developments
    • 13.3.5 Spain
      • 13.3.5.1 Approved Products
      • 13.3.5.2 Market Size and Forecast
      • 13.3.5.3 Key Developments
    • 13.3.6 Netherlands
      • 13.3.6.1 Approved Products
      • 13.3.6.2 Market Size and Forecast
      • 13.3.6.3 Key Developments
    • 13.3.7 Russia
      • 13.3.7.1 Approved Products
      • 13.3.7.2 Market Size and Forecast
    • 13.3.8 Rest-of-Europe
      • 13.3.8.1 Market Size and Forecast
      • 13.3.8.2 Key Developments
  • 13.4 Asia-Pacific
    • 13.4.1 Japan
      • 13.4.1.1 Approved Products
      • 13.4.1.2 Market Size and Forecast
      • 13.4.1.3 Key Developments
    • 13.4.2 China
      • 13.4.2.1 Approved Products
      • 13.4.2.2 Market Size and Forecast
      • 13.4.2.3 Key Developments
    • 13.4.3 Australia
      • 13.4.3.1 Approved Products
      • 13.4.3.2 Market Size and Forecast
      • 13.4.3.3 Key Developments
    • 13.4.4 South Korea
      • 13.4.4.1 Approved Products
      • 13.4.4.2 Market Size and Forecast
      • 13.4.4.3 Key Developments
    • 13.4.5 India
      • 13.4.5.1 Approved Products
    • 13.4.6 Singapore
      • 13.4.6.1 Market Size and Forecast
      • 13.4.6.2 Key Developments
    • 13.4.7 Rest-of-Asia-Pacific
      • 13.4.7.1 Market Size and Forecast
      • 13.4.7.2 Key Developments
  • 13.5 Latin America
    • 13.5.1 Brazil
      • 13.5.1.1 Market Size and Forecast
    • 13.5.2 Mexico
      • 13.5.2.1 Market Size and Forecast
    • 13.5.3 Rest-of-Latin America
      • 13.5.3.1 Market Size and Forecast
  • 13.6 Rest-of-World
    • 13.6.1 Market Size and Forecast

14 Competitive Landscape

  • 14.1 Key Developments and Strategies
    • 14.1.1 Overview
    • 14.1.2 Regulatory and Legal Developments
    • 14.1.3 Synergistic Activities
    • 14.1.4 M&A Activities
    • 14.1.5 Funding Activities
  • 14.2 Market Share Analysis

15 Company Profiles

  • 15.1 Overview
  • 15.2 Amgen Inc.
    • 15.2.1 Company Overview
    • 15.2.2 Role of Amgen Inc. in the Global Cell and Gene Therapy Drug Delivery Devices Market
    • 15.2.3 Financials
    • 15.2.4 R&D Expenditure, 2017-2019
    • 15.2.5 SWOT Analysis
  • 15.3 Bausch & Lomb Incorporated.
    • 15.3.1 Company Overview
    • 15.3.2 Role of Bausch & Lomb Incorporated., in the Global Cell and Gene Therapy Drug Delivery Devices Market
    • 15.3.3 Financials
    • 15.3.4 Key Insights About Financial Health of the Company
    • 15.3.5 SWOT Analysis
  • 15.4 Becton, Dickinson and Company
    • 15.4.1 Company Overview
    • 15.4.2 Role of Becton, Dickinson and Company in the Global Cell and Gene Therapy Drug Delivery Devices Market
    • 15.4.3 Financials
    • 15.4.4 Key Insights About Financial Health of the Company
    • 15.4.5 SWOT Analysis
  • 15.5 Bluebird bio, Inc.
    • 15.5.1 Company Overview
    • 15.5.2 Role of Bluebird bio, Inc. in the Global Cell and Gene Therapy Drug Delivery Devices Market
    • 15.5.3 Financials
    • 15.5.4 R&D Expenditure, 2017-2019
    • 15.5.5 SWOT Analysis
  • 15.6 Castle Creek Biosciences, Inc. (Fibrocell Science, Inc.)
    • 15.6.1 Company Overview
    • 15.6.2 Role of Castle Creek Biosciences, Inc. in the Global Cell and Gene Therapy Drug Delivery Devices Market
    • 15.6.3 Key Insights About Financial Health of the Company
    • 15.6.4 SWOT Analysis
  • 15.7 Dendreon Pharmaceuticals LLC.
    • 15.7.1 Company Overview
    • 15.7.2 Role of Dendreon Pharmaceuticals LLC. in the Global Cell and Gene Therapy Drug Delivery Devices Market
    • 15.7.3 SWOT Analysis
  • 15.8 Helixmith Co., Ltd (ViroMed Co., Ltd)
    • 15.8.1 Company Overview
    • 15.8.2 Role of Helixmith Co., Ltd. in the Global Cell and Gene Therapy Drug Delivery Devices Market
    • 15.8.3 Financials
    • 15.8.4 SWOT Analysis
  • 15.9 Human Stem Cells Institute
    • 15.9.1 Company Overview
    • 15.9.2 Role of Human Stem Cell Institute in Global Cell and Gene Therapy Drug Delivery Devices Market
    • 15.9.3 SWOT Analysis
  • 15.1 Kite Pharma, Inc.
    • 15.10.1 Company Overview
    • 15.10.2 Role of Kite Pharma, Inc in Global Cell and Gene Therapy Drug Delivery Devices Market
    • 15.10.3 Financials
    • 15.10.4 R&D Expenditure, 2017-2019
    • 15.10.5 SWOT Analysis
  • 15.11 Kolon TissueGene, Inc.
    • 15.11.1 Company Overview
    • 15.11.2 Role of Kolon TissueGene, Inc. in the Global Cell and Gene Therapy Drug Delivery Devices Market
    • 15.11.3 SWOT Analysis
  • 15.12 Novartis AG
    • 15.12.1 Company Overview
    • 15.12.2 Role of Novartis AG in the Global Cell and Gene Therapy Drug Delivery Devices Market
    • 15.12.3 Financials
    • 15.12.4 R&D Expenditure, 2017-2019
    • 15.12.5 SWOT Analysis
  • 15.13 Orchard Therapeutics plc.
    • 15.13.1 Company Overview
    • 15.13.2 Role of Orchard Therapeutics plc. in the Global Cell and Gene Therapy Drug Delivery Devices Market
    • 15.13.3 Financials
    • 15.13.4 SWOT Analysis
  • 15.14 Pfizer, Inc.
    • 15.14.1 Company Overview
    • 15.14.2 Role of Pfizer, Inc. in the Global Cell and Gene Therapy Drug Delivery Devices Market
    • 15.14.3 Financials
    • 15.14.4 R&D Expenditure, 2017-2019
    • 15.14.5 SWOT Analysis
  • 15.15 Renova Therapeutics
    • 15.15.1 Company Overview
    • 15.15.2 Role of Renova Therapeutics in Global Cell and Gene Therapy Drug Delivery Devices Market
    • 15.15.3 SWOT Analysis
  • 15.16 Spark Therapeutics, Inc.
    • 15.16.1 Company Overview
    • 15.16.2 Role of Spark Therapeutics, Inc. in Global Cell and Gene Therapy Drug Delivery Devices Market
    • 15.16.3 Financials
    • 15.16.4 Key Insights About Financial Health of the Company
    • 15.16.5 SWOT Analysis
  • 15.17 uniQure N.V.
    • 15.17.1 Company Overview
    • 15.17.2 Role of uniQure N.V. in Global Cell and Gene Therapy Drug Delivery Devices Market
    • 15.17.3 SWOT Analysis
  • 15.18 Vericel Corporation
    • 15.18.1 Company Overview
    • 15.18.2 Role of Vericel Corporation in the Global Cell and Gene Therapy Drug Delivery Devices Market
    • 15.18.3 Financials
    • 15.18.4 Key Insights About Financial Health of the Company
    • 15.18.5 SWOT Analysis

List of Tables

  • Table 1: Evolution of Controlled Drug Delivery Systems: 30 Years (2000-2030)
  • Table 5.1: Drug Delivery Methods of Cell and Gene Therapeutics
  • Table 5.2: Commercialized Drugs of Cell and Gene Therapy Drug Delivery Devices Market, Device Size and Specification
  • Table 5.3: Comparison of Major Routes of Drug Delivery for Systemic Absorption
  • Table 6.1: Ongoing Clinical Trials of Drug Delivery Systems
  • Table 6.2: Commercialized Drugs of Cell and Gene Therapy Drug Delivery Devices Market
  • Table 7.1: Pipeline Drug Delivery Devices for Cell and Gene Therapy
  • Table 7.2: Drug Delivery Based on Lab-on-a-Chip Technology
  • Table 7.3: Nanomaterials and Nanobiotechnologies used for Drug Delivery
  • Table 7.4: Globally Approved Lipid Nanoparticles Therapies
  • Table 8.1: Commercialized Cell and Gene Therapies in the Market
  • Table 8.2: Filing Requirements for Pre-Filled Syringes
  • Table 8.3: Differentiation of an Injectable Therapeutic Throughout its Life Cycle
  • Table 9.1: European Commission Medical Device Directives
  • Table 9.2: Federal Agencies of EU Member States
  • Table 9.3: Key Market Access Landscape (9 Countries), January 2019
  • Table 9.4: Average Selling Price of Cell and Gene Therapy Drug Delivery Devices, (2019 and 2030)
  • Table 10.1: Patents for Cell and Gene Therapy Drug Delivery Devices
  • Table 13.1: List of Cell and Gene Therapy Products with Marketing Authorization in the European Union by EMA

List of Figures

  • Figure 1: Global Geriatric Population by Age
  • Figure 2: Global Cell and Gene Therapy Drug Delivery Devices Market Snapshot
  • Figure 3: Dominant Segments of the Global Cell and Gene Therapy Drug Delivery Devices Market, 2019 and 2030
  • Figure 4: Global Cell and Gene Therapy Drug Delivery Devices Market (by Product Type), 2019 and 2030
  • Figure 5: Global Cell and Gene Therapy Drug Delivery Devices Market (by Region), 2019 and 2030
  • Figure 6: Global Cell and Gene Therapy Drug Delivery Devices: Impact Analysis
  • Figure 7: Leading Players in Global Cell and Gene Therapy Drug Delivery Devices Market
  • Figure 2.1: Global Cell and Gene Therapy Drug Delivery Devices Market Segmentation
  • Figure 4.1: Global Cell and Gene Therapy Drug Delivery Devices Market Methodology
  • Figure 4.2: Primary Research Methodology
  • Figure 4.3: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 4.4: Top-Down Approach (Segment-Wise Analysis)
  • Figure 5.1: Clinical Trials by Therapeutic Category, Cell and Gene Therapy, 2018
  • Figure 6.1: Global Cell and Gene Therapy Drug Delivery Devices Market, $Thousand, 2019 and 2030
  • Figure 6.2: Cell and Gene Therapy Clinical Trials (by Phase)
  • Figure 6.3: Global Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
  • Figure 6.4: Cell and Gene Therapy Drug Delivery Devices Market (by Commercialized Products) 2019
  • Figure 6.5: Cell and Gene Therapy Drug Delivery Devices Market (by Commercialized Products), 2030
  • Figure 6.6: Most Impacted Practices in Cell and Gene Therapy Drug Delivery Devices Market
  • Figure 6.7: Impact of COVID-19 on Cell and Gene Therapy Drug Delivery Devices Market
  • Figure 6.8: Major Areas of Disruption
  • Figure 6.9: Impact of COVID-19 on Clinical Trials
  • Figure 6.10: Status of Clinical Trials (April 2020-July 2020)
  • Figure 6.11: Disrupted Clinical Trials (by Phase of Clinical Trial)
  • Figure 6.12: Disrupted Clinical Trials (by Therapy Area)
  • Figure 7.1: Interrelationship of Drug Delivery Devices, Pharmaceutical Industry, and Biotechnology
  • Figure 8.1: Global Cell and Gene Therapy Drug Delivery Devices: Impact Analysis
  • Figure 8.2: Total Burden of Diseases (by Cause), 2017
  • Figure 8.3: Number of Active and Completed Clinical Trials for Cell and Gene Therapy, 2014-2018
  • Figure 8.4: Total Percutaneous Injuries Reported by Drug Delivery Device
  • Figure 9.1: Risk Assessment of Medical Devices
  • Figure 9.2: FDA Regulatory Pathway for Medical Device
  • Figure 9.3: FDA Regulations Modification: Pre-COVID-19 Phase to Post-COVID-19 Phase
  • Figure 9.4: EU Regulatory Pathway for Medical Device
  • Figure 9.5: European Commission Regulations Modification: Pre-COVID-19 Phase to Post-COVID-19 Phase
  • Figure 9.6: Regulatory and Market Access Challenges in Asia-Pacific
  • Figure 9.7: Regulatory Environment for Medical Devices in China
  • Figure 9.8: Chinese Medical Device Classification and Pre-Market Requirement
  • Figure 10.1: Share of Patents (by Ownership), 2016-2019
  • Figure 11.1: Revenue Contribution of Different Segments, 2020 and 2030
  • Figure 11.2: Subretinal Injection Cannula (by Volume), 2019-2030
  • Figure 11.3: Subretinal Injection Cannula (by Value), 2019-2030
  • Figure 11.4: Extension Tube (by Volume), 2019-2030
  • Figure 11.5: Extension Tube (by Value), 2019-2030
  • Figure 11.6: Intravenous Catheter (by Volume), 2019-2030
  • Figure 11.7: Intravenous Catheter (by Value), 2019-2030
  • Figure 11.8: Revenue Contribution of Sterile Insulin Syringe Segments, 2019 and 2030
  • Figure 11.9: Sterile Insulin Syringe (Size 1.0 ML, 31-Gauge Needle) (by Volume), 2019-2030
  • Figure 11.10: Sterile Insulin Syringe (Size 1.0 ML, 31-Gauge Needle) (by Value), 2019-2030
  • Figure 11.11: Sterile Insulin Syringe (Size 0.5 ML, 22 Gauge Needle) (by Volume), 2019-2030
  • Figure 11.12: Sterile Insulin Syringe (Size 0.5 ML, 22 Gauge Needle) (by Value), 2019-2030
  • Figure 11.13: Revenue Contribution of Pre-Filled Syringe Segments, 2019 and 2030
  • Figure 11.14: Pre-Filled Syringe (Size 1.0 ML, 22-26 Gauge Needle) (by Volume), 2019-2030
  • Figure 11.15: Pre-Filled Syringe (Size 1.0 ML, 22-26 Gauge Needle) (by Value), 2019-2030
  • Figure 11.16: Pre-Filled Syringe (Size 4.0 ML, 22-26 Gauge Needle) (by Volume), 2019-2030
  • Figure 11.17: Pre-Filled Syringe (Size 4.0 ML, 22-26 Gauge Needle) (by Value), 2019-2030
  • Figure 11.18: Revenue Contribution of Infusion Bag Segments, 2019 and 2030
  • Figure 11.19: Infusion Bag (Size 10 ML to 50 ML) (by Volume), 2019-2030
  • Figure 11.20: Infusion Bag (Size 10 ML to 50 ML) (by Value), 2019-2030
  • Figure 11.21: Infusion Bag (68 ML) (by Volume), 2019-2030
  • Figure 11.22: Infusion Bag (68 ML) (by Value), 2019-2030
  • Figure 11.23: Infusion Bag (60 ML) (by Volume), 2019-2030
  • Figure 11.24: Infusion Bag (60 ML) (by Value), 2019-2030
  • Figure 11.25: Infusion Bag (Size Up to 65 ML) (by Volume), 2019-2030
  • Figure 11.26: Infusion Bag (Size Up to 65 ML) (by Value), 2019-2030
  • Figure 12.1: Luxturna Drug Delivery Devices (by Volume), 2019 and 2030
  • Figure 12.2: Luxturna Drug Delivery Devices (by Value), 2019 and 2030
  • Figure 12.3: Kymriah Drug Delivery Devices (by Volume), 2019 and 2030
  • Figure 12.4: Kymriah Drug Delivery Devices (by Value), 2019 and 2030
  • Figure 12.5: Provenge Drug Delivery Devices (by Volume), 2019 and 2030
  • Figure 12.6: Provenge Drug Delivery Devices (by Value), 2019 and 2030
  • Figure 12.7: Zolgensma Drug Delivery Devices (by Volume), 2019 and 2030
  • Figure 12.8: Zolgensma Drug Delivery Devices (by Value), 2019 and 2030
  • Figure 12.9: Yescarta Drug Delivery Devices (by Volume), 2019 and 2030
  • Figure 12.10: Yescarta Drug Delivery Devices (by Value), 2019 and 2030
  • Figure 12.11: Strimvelis Drug Delivery Devices (by Volume), 2019 and 2030
  • Figure 12.12: Strimvelis Drug Delivery Devices (by Value), 2019 and 2030
  • Figure 13.1: Global Cell and Gene Therapy Drug Delivery Devices Market (by Region)
  • Figure 13.2: Global Cell and Gene Therapy Drug Delivery Devices Market (by Region), 2019 and 2030
  • Figure 13.3: North America Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
  • Figure 13.4: North America: Market Dynamics
  • Figure 13.5: U.S. Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
  • Figure 13.6: Projections of the Older Adult Population in the U.S.: 2016 to 2060 (Thousand)
  • Figure 13.7: Canada Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
  • Figure 13.8: Europe Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
  • Figure 13.9: Europe-Market Dynamics
  • Figure 13.10: Germany Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
  • Figure 13.11: France Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
  • Figure 13.12: U.K. Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
  • Figure 13.13: Italy Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
  • Figure 13.14: Spain Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
  • Figure 13.15: Netherlands Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
  • Figure 13.16: Russia Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
  • Figure 13.17: Rest-of-Europe Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
  • Figure 13.18: Europe Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
  • Figure 13.19: Asia-Pacific: Market Dynamics
  • Figure 13.20: Japan Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
  • Figure 13.21: China Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
  • Figure 13.22: Australia Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
  • Figure 13.23: South Korea Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
  • Figure 13.24: Singapore Cell and Gene Therapy Drug Delivery Devices Market, 2020-2030
  • Figure 13.25: Rest-of-Asia-Pacific Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
  • Figure 13.26: Latin America Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
  • Figure 13.27: Latin America: Market Dynamics
  • Figure 13.28: Brazil Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
  • Figure 13.29: Mexico Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
  • Figure 13.30: Rest-of-Latin America Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
  • Figure 13.31: Rest-of-World Cell and Gene Therapy Drug Delivery Devices Market, 2020-2030
  • Figure 14.1: Share of Key Developments and Strategies, January 2016-January 2021
  • Figure 14.2: Regulatory and Legal Developments Share (by Company), January 2016-January 2021
  • Figure 14.3: Synergistic Activities (by Company), January 2016-January 2021
  • Figure 14.4: Company Share (by Synergistic Activity), January 2016-January 2021
  • Figure 14.5: M&A Activities Share (by Company), January 2016-January 2021
  • Figure 14.6: Funding Activities (by Company), January 2016-January 2021
  • Figure 14.7: Market Share Analysis for the Global Cell Therapy and Gene Drug Delivery Devices Market, 2019
  • Figure 15.1: Total Number of Companies Profiled
  • Figure 15.2: Amgen Inc.: Overall Product Portfolio
  • Figure 15.3: Amgen Inc.: Pipeline Product Portfolio
  • Figure 15.4: Amgen, Inc.: Overall Financials, 2017-2019
  • Figure 15.5: Amgen, Inc.: Sales (by Product), 2017-2019
  • Figure 15.6: Amgen, Inc.: Revenue (by Region), 2017-2019
  • Figure 15.7: Amgen, Inc.: R&D Expenditure, 2017-2019
  • Figure 15.8: Amgen Inc.: SWOT Analysis
  • Figure 15.9: Product Portfolio: Bausch & Lomb Incorporated.,
  • Figure 15.10: Bausch & Lomb Incorporated.: Overall Financials, 2017-2019
  • Figure 15.11: Bausch & Lomb Incorporated.: R&D Expenditure, 2017-2019
  • Figure 15.12: Bausch & Lomb Incorporated.: SWOT Analysis
  • Figure 15.13: Becton, Dickinson and Company: Overall Financials, 2017-2019
  • Figure 15.14: Becton, Dickinson and Company: Revenue (by Segment), 2017-2019
  • Figure 15.15: Becton, Dickinson and Company: Revenue Split for BD Life Sciences, 2017-2019
  • Figure 15.16: Becton, Dickinson and Company: Revenue (by Region), 2017-2019
  • Figure 15.17: Becton, Dickinson and Company: R&D Expenditure, 2017-2019
  • Figure 15.19: Pipeline Product Portfolio: Bluebird Bio, Inc.
  • Figure 15.20: Bluebird Bio Inc: Overall Financials, 2017-2019
  • Figure 15.21: Bluebird Bio Inc: R&D Expenditure, 2017-2019
  • Figure 15.22: bluebird bio, Inc.: SWOT Analysis
  • Figure 15.23: Castle Creek Biosciences, Inc.: Overall Product Portfolio
  • Figure 15.24: Castle Creek Biosciences, Inc.: Pipeline Product Portfolio
  • Figure 15.25: Castle Creek Biosciences, Inc.: R&D Expenditure, 2017-2018
  • Figure 15.26: Castle Creek Biosciences, Inc.: SWOT Analysis
  • Figure 15.27: Dendreon Pharmaceuticals LLC: Product Portfolio
  • Figure 15.28: Dendreon Pharmaceuticals LLC.: SWOT Analysis
  • Figure 15.29: Helixmith Co., Ltd.: Pipeline Product Portfolio
  • Figure 15.30: ViroMed Co: Overall Financials, 2016-2018
  • Figure 15.31: Helixmith Co., Ltd.: SWOT Analysis
  • Figure 15.32: Human Stem Cell Institute: Overall Product Portfolio
  • Figure 15.33: Human Stem Cell Institute: SWOT Analysis
  • Figure 15.34: Kite Pharma, Inc: Overall Product Portfolio
  • Figure 15.35: Kite Pharma, Inc.: Pipeline Product Portfolio
  • Figure 15.36: Kite Pharma, Inc: Overall Financials, 2017-2019
  • Figure 15.37: Kite Pharma, Inc: Revenue (by Segment), 2017-2019
  • Figure 15.38: Kite Pharma, Inc: Revenue (by Region), 2017-2019
  • Figure 15.39: Kite Pharma, Inc: R&D Expenditure, 2017-2019
  • Figure 15.40: Kite Pharma, Inc.: SWOT Analysis
  • Figure 15.41: Kolon TissueGene, Inc.: Pipeline Product Portfolio
  • Figure 15.42: Kolon TissueGene, Inc.: SWOT Analysis
  • Figure 15.43: Novartis AG: Overall Product Portfolio
  • Figure 15.44: Novartis AG: Pipeline Product Portfolio
  • Figure 15.45: Novartis AG: Overall Financials, 2017-2019
  • Figure 15.46: Novartis AG Net Revenue (by Business Segment), 2017-2019
  • Figure 15.47: Novartis AG: Net Revenue (by Region), 2017-2019
  • Figure 15.48: Novartis AG: R&D Expense, 2017-2019
  • Figure 15.49: Novartis AG: SWOT Analysis
  • Figure 15.50: Orchard Therapeutics plc.: Pipeline Product Portfolio
  • Figure 15.51: Orchard Therapeutics plc.: Overall Financials, 2016-2018
  • Figure 15.52: Orchard Therapeutics plc: SWOT Analysis
  • Figure 15.53: Pfizer, Inc.: Pipeline Product Portfolio
  • Figure 15.54: Pfizer Inc.: Overall Financials, 2017-2019
  • Figure 15.55: Pfizer Inc.: Revenue (by Segment), 2017-2019
  • Figure 15.56: Pfizer Inc.: Revenue Split (by Biopharma Segment), 2017-2019
  • Figure 15.57: Pfizer Inc.: Revenue (by Region), 2017-2019
  • Figure 15.58: Pfizer Inc: R&D Expenditure, 2017-2019
  • Figure 15.59: Pfizer, Inc.: SWOT Analysis
  • Figure 15.60: Renova Therapeutics: Pipeline Product Portfolio
  • Figure 15.61: Renova Therapeutics: SWOT Analysis
  • Figure 15.62: Spark Therapeutics, Inc.: Overall Product Portfolio
  • Figure 15.63: Spark Therapeutics, Inc.: Pipeline Product Portfolio
  • Figure 15.64: Spark Therapeutics, Inc.: Overall Financials, 2015-2017
  • Figure 15.65: Spark Therapeutics, Inc.: R&D Expenditure, 2015-2017
  • Figure 15.66: Spark Therapeutics, Inc.: SWOT Analysis
  • Figure 15.67: uniQure N.V.: Pipeline Product Portfolio
  • Figure 15.68: uniQure N.V.: SWOT Analysis
  • Figure 15.69: Vericel Corporation: Overall Product Portfolio
  • Figure 15.70: Vericel Corporation: Pipeline Product Portfolio
  • Figure 15.71: Vericel Corporation: Overall Financials, 2016-2018
  • Figure 15.72: Vericel Corporation: Revenue (by Product), 2016-2018
  • Figure 15.73: Vericel Corporation: R&D Expenditure (2016-2018)
  • Figure 15.74: Vericel Corporation: SWOT Analysis